van Asperen CJ - Search Results

1

CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer.

Huijts PE, Hollestelle A, Balliu B, Houwing-Duistermaat JJ, Meijers CM, Blom JC, Ozturk B, Krol-Warmerdam EM, Wijnen J, Berns EM, Martens JW, Seynaeve C, Kiemeney LA, van der Heijden HF, Tollenaar RA, Devilee P, van Asperen CJ. Huijts PE, et al. Among authors: van asperen cj, van der heijden hf. Eur J Hum Genet. 2014 Jan;22(1):46-51. doi: 10.1038/ejhg.2013.85. Epub 2013 May 8. Eur J Hum Genet. 2014. PMID: 23652375 Free PMC article.

2

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P. Oldenburg RA, et al. Among authors: van asperen cj. Cancer Res. 2003 Dec 1;63(23):8153-7. Cancer Res. 2003. PMID: 14678969

3

Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines.

Vink GR, van Asperen CJ, Devilee P, Breuning MH, Bakker E. Vink GR, et al. Among authors: van asperen cj. Eur J Hum Genet. 2005 May;13(5):525-7. doi: 10.1038/sj.ejhg.5201379. Eur J Hum Genet. 2005. PMID: 15741995 No abstract available.

4

Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.

van Puijenbroek M, van Asperen CJ, van Mil A, Devilee P, van Wezel T, Morreau H. van Puijenbroek M, et al. Among authors: van asperen cj, van mil a, van wezel t. J Pathol. 2005 Jun;206(2):198-204. doi: 10.1002/path.1764. J Pathol. 2005. PMID: 15818573

5

Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A. van Oostrom I, et al. Among authors: van asperen cj, van gool ar. Patient Educ Couns. 2007 Jan;65(1):58-68. doi: 10.1016/j.pec.2006.05.006. Epub 2006 Jul 26. Patient Educ Couns. 2007. PMID: 16872788

6

Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.

van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W. van Dijk S, et al. Among authors: van asperen cj. J Clin Oncol. 2006 Aug 1;24(22):3672-7. doi: 10.1200/JCO.2005.03.7259. J Clin Oncol. 2006. PMID: 16877736

7

A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Riedijk SR, van Dooren S, Tibben A. van Oostrom I, et al. Among authors: van asperen cj, van dooren s, van gool ar. Psychooncology. 2007 Apr;16(4):320-8. doi: 10.1002/pon.1062. Psychooncology. 2007. PMID: 16909428

8

Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A. van Oostrom I, et al. Among authors: van asperen cj, van gool ar. Eur J Cancer. 2007 Jan;43(1):71-7. doi: 10.1016/j.ejca.2006.08.023. Epub 2006 Oct 11. Eur J Cancer. 2007. PMID: 17045473

9

The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective study.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A. van Oostrom I, et al. Among authors: van asperen cj, van gool ar. Psychooncology. 2007 Dec;16(12):1121-9. doi: 10.1002/pon.1178. Psychooncology. 2007. PMID: 17328098

10

Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort.

Jacobi CE, van Ierland Y, van Asperen CJ, Hallensleben E, Devilee P, Jan Fleuren G, Kenter GG. Jacobi CE, et al. Among authors: van asperen cj, van ierland y. Genet Med. 2007 Mar;9(3):173-9. doi: 10.1097/GIM.0b013e318032e4ab. Genet Med. 2007. PMID: 17413421 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

220 results

Search Page